alpha2-antiplasmin monoclonal antibody

Alpha2-antiplasmin monoclonal antibodies are a class of investigational thrombolytic agents designed to target and inhibit alpha2-antiplasmin (α2AP), the primary physiological inhibitor of plasmin. By blocking α2AP, these antibodies prevent the rapid inactivation of plasmin, thereby enhancing endogenous fibrinolysis and promoting the dissolution of blood clots. Unlike traditional plasminogen activators (such as tPA or tenecteplase) which can cause systemic fibrinogen depletion and increase bleeding risks, anti-α2AP antibodies are designed to facilitate localized clot lysis with a potentially safer bleeding profile. Key clinical-stage candidates in this class include TS23 (developed by Translational Sciences and licensed by CSL) and BAY3018250 (developed by Bayer), which are being evaluated for indications such as acute ischemic stroke, pulmonary embolism, and deep vein thrombosis.

Other names

alpha2-antiplasmin antibodyalpha-2-antiplasmin antibodyalpha 2-antiplasmin antibodyanti-a2AP antibodyanti-a-2AP antibodyanti-a 2AP antibodyanti-a2AP monoclonal antibodyanti-a-2AP monoclonal antibodyanti-a 2AP monoclonal antibodyanti-alpha2-antiplasmin antibodyanti-alpha-2-antiplasmin antibodyanti-alpha 2-antiplasmin antibodyanti-alpha2-antiplasmin monoclonal antibodyanti-alpha-2-antiplasmin monoclonal antibodyanti-alpha 2-antiplasmin monoclonal antibody